Parkinson disease (ORPHA:411)

GPTKB entity

Predicate	Object
gptkbp:instanceOf	neurodegenerative disease rare disease
gptkbp:affects	gptkb:nervous_system
gptkbp:associatedWith	gptkb:PARK2_gene gptkb:DJ-1_gene gptkb:LRRK2_gene gptkb:PINK1_gene gptkb:SNCA_gene
gptkbp:complication	gptkb:dementia gptkb:pneumonia falls autonomic dysfunction dysphagia
gptkbp:firstDescribed	gptkb:James_Parkinson 1817
gptkbp:hasDiagnosticCriteria	response to levodopa clinical diagnosis imaging (DaTscan)
gptkbp:hasOrphanetID	411
gptkbp:hasUMLS_CUI	C0030567
https://www.w3.org/2000/01/rdf-schema#label	Parkinson disease (ORPHA:411)
gptkbp:ICD-10_code	gptkb:G20
gptkbp:inheritance	autosomal dominant autosomal recessive sporadic
gptkbp:MeSH_ID	D010300
gptkbp:OMIM	168600
gptkbp:onset	elderly middle age
gptkbp:pathology	Lewy bodies loss of dopaminergic neurons in substantia nigra
gptkbp:prevalence	increases with age 1-2 per 1,000 population
gptkbp:prognosis	progressive variable
gptkbp:riskFactor	age family history exposure to pesticides male sex
gptkbp:symptom	gptkb:depression bradykinesia postural instability resting tremor shuffling gait cognitive impairment muscle rigidity hypophonia masked facies micrographia
gptkbp:synonym	gptkb:Parkinson's_disease gptkb:Idiopathic_Parkinson_disease gptkb:Primary_Parkinsonism
gptkbp:treatment	gptkb:levodopa physical therapy MAO-B inhibitors deep brain stimulation dopamine agonists
gptkbp:bfsParent	gptkb:idiopathic_Parkinson's_disease
gptkbp:bfsLayer	6